Arcutis Biotherapeutics, Inc. (ARQT)
| Market Cap | 3.44B +2.8% |
| Revenue (ttm) | 508.68M +60.0% |
| Net Income | 29.91M |
| EPS | 0.22 |
| Shares Out | 126.46M |
| PE Ratio | 125.28 |
| Forward PE | 39.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,330,792 |
| Open | 27.74 |
| Previous Close | 27.61 |
| Day's Range | 26.99 - 28.17 |
| 52-Week Range | 19.30 - 34.80 |
| Beta | 1.63 |
| Analysts | Buy |
| Price Target | 40.38 (+48.62%) |
| Earnings Date | Nov 4, 2026 |
About ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Bio... [Read more]
Financial Performance
In 2025, Arcutis Biotherapeutics's revenue was $376.07 million, an increase of 91.34% compared to the previous year's $196.54 million. Losses were -$16.14 million, -88.47% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ARQT stock is "Buy." The 12-month stock price target is $40.38, which is an increase of 48.62% from the latest price.
News
Arcutis reports caregiver-reported outcomes data from INTEGUMENT-INFANT trial
Arcutis Biotherapeutics (ARQT) announced new caregiver-reported outcomes data from the INTEGUMENT-INFANT trial supporting Zoryve cream 0.05% in the treatment of infants with mild to moderate atopic de...
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting
New INTEGUMENT-INFANT trial results demonstrate improvements in itch, reductions in symptoms, and improvements in quality of life for infants with atopic dermatitis and their families Findings further...
Arcutis Biotherapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
2026 outperformance and expanded commercial reach underpin confidence in further 2027 growth, supported by pediatric milestones and a large non-steroidal market opportunity. Management cited $2.3B-$3.5B peak sales potential and positive cash flow since late 2025.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in i...
Arcutis Biotherapeutics enrolls first patient in INTEGUMENT-3 trial
Arcutis Biotherapeutics (ARQT) announced that the first participant has been enrolled in a Phase 3, double-blind, randomized, vehicle-controlled study, INTEGUMENT-3. The study is designed to evaluate ...
Arcutis Biotherapeutics price target raised to $40 from $35 at TD Cowen
TD Cowen raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $40 from $35 and keeps a Buy rating on the shares. The firm said Zoryve sales of $144MM…
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitis Study aims to expand once-daily ZOR...
Arcutis Biotherapeutics raises FY26 revenue view to $535M-$545M from $525M-$540M
Consensus $538.56M. The company said, “The company raised net product sales guidance for the full year 2026 to $535M-$545M from $525M-$540M.”
Arcutis Biotherapeutics Earnings Call Transcript: Q3 2026
Q3 revenue rose 45% YoY to $143.9M, prompting higher FY 2026 guidance of $535M-$545M. Demand remained strong, while commercial and pipeline investment is aimed at a 2027 sales inflection.
Arcutis Biotherapeutics Earnings release: Q3 2026
Arcutis Biotherapeutics released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Arcutis Biotherapeutics Quarterly report: Q3 2026
Arcutis Biotherapeutics has published its Q3 2026 quarterly earnings report on November 4, 2026.
Arcutis Biotherapeutics Slides: Q3 2026
Arcutis Biotherapeutics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Arcutis Biotherapeutics reports Q3 EPS 6c, consensus 17c
Reports Q3 revenue $143.92M, consensus $142.59M. “Yet another strong quarter of performance reflects the consistent execution of our corporate strategy and further strengthens our financial position. ...
Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q3 revenues of $143.9 million, +45% versus Q3 of 2025, and +11% versus Q2 of 2026, driven by strong demand growth Raised 2026 fu...
Arcutis Appoints Rob Scott, MD to Board of Directors
Rob Scott, MD has been appointed to the Arcutis Board of Directors effective October 23, 2026. Dr. Scott is a global pharma industry leader and pioneer.
Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
WESTLAKE VILLAGE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in i...
Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
Arcutis today announced that it will report its Q3 2026 financial results and provide a business update after the U.S. financial markets close on Nov 4.
Arcutis Biotherapeutics price target raised to $44 from $38 at Guggenheim
Guggenheim raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $44 from $38 and keeps a Buy rating on the shares. The firm has “growing conviction that 2027 should…
Arcutis Biotherapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse initiated coverage of Arcutis Biotherapeutics (ARQT) with an Overweight rating and $48 price target Arcutis is building a topical dermatology franchise around...
Arcutis Biotherapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse initiated coverage of Arcutis Biotherapeutics (ARQT) with an Overweight rating and $48 price target
Arcutis Biotherapeutics presents data across Zoryve portfolio
Arcutis Biotherapeutics (ARQT) announced data presented across its Zoryve portfolio as well as real-world research on the long-term use of topical corticosteroids at the 35th European Academy of Derma...
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to
Arcutis' ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
Newly created award category highlights innovation in prescription skin treatment ZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is ...
Arcutis Biotherapeutics partners with Simone Biles for new awareness campaign
Arcutis Biotherapeutics (ARQT) announced that World Champion gymnast Simone Biles has partnered with the company to launch its Skin to Believe In awareness campaign. The campaign encourages the approx...
Arcutis Biotherapeutics falls -5.1%
Arcutis Biotherapeutics (ARQT) is down -5.1%, or -$1.33 to $24.81.